ASCO 2026

News

ASCO26: Verzenio gives hope of liposarcoma treatment advance

The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.

News

ASCO26: Could AL amyloidosis see a new crop of therapies?

Trials of AstraZeneca's anselamimab and Regeneron's Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.

News

ASCO26: DNA test could spare breast cancer patients chemo

Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.

Patients

ASCO 26: War, disasters, policy compound cancer care challen...

A Friday ASCO session highlighted the challenges faced by cancer patients in situations of geopolitical crisis, as presenters called for more support.

Oncology

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

Pharmaphorum caught up with Johanna Bendell, Pfizer’s chief development officer for oncology, to learn about what the company is bringing to ASCO.

News

ASCO26: Revolution's 'grand slam' data in pancreatic cancer

Revolution Medicines' pan-RAS(on) inhibitor daraxonrasib has delivered an unprecedented result in pancreatic cancer.

ASCO26: Verzenio gives hope of liposarcoma treatment advance

ASCO26: Could AL amyloidosis see a new crop of therapies?

ASCO26: DNA test could spare breast cancer patients chemo

ASCO 26: War, disasters, policy compound cancer care challen...

ASCO 26: Three strong Pfizer phase 3s, with Johanna Bendell

ASCO26: Revolution's 'grand slam' data in pancreatic cancer

BioMarin snaps up Alesta's lead asset for $275M

Discover a new era of healthcare panel engagement: Grounded ...

ASCO 2026

Editor's Picks